2021
DOI: 10.1016/s1470-2045(21)00574-x
|View full text |Cite
|
Sign up to set email alerts
|

mRNA-1273 COVID-19 vaccination in patients receiving chemotherapy, immunotherapy, or chemoimmunotherapy for solid tumours: a prospective, multicentre, non-inferiority trial

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

18
181
1

Year Published

2022
2022
2024
2024

Publication Types

Select...
8

Relationship

1
7

Authors

Journals

citations
Cited by 142 publications
(200 citation statements)
references
References 27 publications
18
181
1
Order By: Relevance
“…Patients with cancer are at higher risk of severe COVID-19 ( Grivas et al., 2021 ; Kuderer et al., 2020 ), and they are currently prioritized globally for a third COVID-19 vaccine dose. Humoral and cellular immune responses are detected after two primary COVID-19 vaccine doses in most patients with cancer ( Ehmsen et al., 2021 ; Fendler et al., 2021 ; Oosting et al., 2021 ), although neutralizing responses against variants of concern (VOCs) are reduced. Neutralizing responses are frequently impaired in patients with hematological malignancies, especially those receiving B cell-depleting therapies ( Ehmsen et al., 2021 ; Fendler et al., 2021 ; Thakkar et al., 2021 ).…”
mentioning
confidence: 99%
“…Patients with cancer are at higher risk of severe COVID-19 ( Grivas et al., 2021 ; Kuderer et al., 2020 ), and they are currently prioritized globally for a third COVID-19 vaccine dose. Humoral and cellular immune responses are detected after two primary COVID-19 vaccine doses in most patients with cancer ( Ehmsen et al., 2021 ; Fendler et al., 2021 ; Oosting et al., 2021 ), although neutralizing responses against variants of concern (VOCs) are reduced. Neutralizing responses are frequently impaired in patients with hematological malignancies, especially those receiving B cell-depleting therapies ( Ehmsen et al., 2021 ; Fendler et al., 2021 ; Thakkar et al., 2021 ).…”
mentioning
confidence: 99%
“…Antibody responses were determined as standard of care in September 2021 using the Abbott SARS-CoV-2 IgG EUA assay. A cut-off level of 300 arbitrary units (AU)/ml was chosen based on a recent analysis showing the association between SARS-CoV-2-binding antibody concentration (BAU/ml) and neutralizing antibody titer that categorized responders into adequate responders (> 300 BAU/mL) and suboptimal responders (> 10 BAU/mL but ≤300 BAU/mL) [ 2 ]. The antibody status of patients prior to vaccination was unknown.…”
mentioning
confidence: 99%
“…A SARS-CoV-2 spike-specific IFNγ T cell response at four weeks after dose 2 was observed in 67% of evaluable patients with chemotherapy, 66% with immunotherapy, and 53% with chemoimmunotherapy, compared to 69% in controls [25]. Of particular interest, a cellular vaccine response was observed in 43% of serological non-responders and 47% of suboptimal responders among cancer patients [25].…”
Section: Anti-cancer Treatments: Chemotherapy Immune Checkpoint Block...mentioning
confidence: 97%
“…As most of these techniques are labor-intensive and time-consuming, few assays have found their way into clinical practice. By far the most frequently used test for vaccine induced T cell response is the IFNγ ELISPOT, which is reported by most diagnostic trials involving large patient populations [8,[24][25][26].…”
Section: Assessment Of T Cell Vaccine Responsementioning
confidence: 99%
See 1 more Smart Citation